About US
Contact us
-
AstraZeneca now has a 'winning formula' for its COVID-19 vaccine, CEO saysAstraZeneca's early COVID-19 trial data not only fell short of Pfizer and Moderna's expectation-beating stats, they raised a host of questionsthanks to a dosing error in one group of trial patients.2020/12/31
-
Moderna’s Covid-19 vaccine obtains Health Canada authorisationModerna has received authorisation for its Covid-19 vaccine from Health Canada for the immunisation of individuals aged 18 years and above. Co-developed by Moderna and NIAID Vaccine Research Center i2020/12/30
-
FDA investigates allergic reactions of Pfizer Covid-19 vaccine in USThe US Food and Drug Administration (FDA) has started investigating around five allergic reactions that occurred after individuals received Pfizer and BioNTech’s Covid-19 shot. Last week,FDA authoris2020/12/30
-
Takeda to divest non-core assets to Hasten Biopharmaceutic for $322mTakeda Pharmaceutical Company has signed an agreement to divest a portfolio of five non-core prescription pharmaceutical assets sold in China to Hasten Biopharmaceutic for $322m. Hasten will gain the2020/12/29
-
Dr. Reddy’s seeks approval from Health Canada for Covid-19 treatmentDr. Reddy’s Canada has filed an application with Health Canada on behalf of the consortium for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate Covid-19 in adult patients. The s2020/12/28
-
Pfizer, Moderna urge calm as they launch tests of vaccines against mutated COVID-19After a mutated, fast-spreading variant of COVID-19 in the U.K. disrupted global travel over the weekend, a troubling question emerged: Will the new vaccines from Pfizer and Moderna work against this2020/12/25
-
2021 forecast: Targeted delivery, oral vaccines and mRNA 2.0: The next generation of drugs and prophylactics in the fight against COVID-19As the chapter closes on the first year of the COVID-19 pandemic, drugmakers are hard at work bolsteringthe defenses mounted in 2020—and they're looking at new formulations and delivery methods to br2020/12/25
-
2021 forecast: M&A poised to rebound in 2021, fueled by pharma's $1.47T in deal-making firepower: analystsWhen AstraZeneca said it would lay out $39 billion for Alexion on Dec. 12—just hours after the first COVID-19 vaccine was approved in the U.S., promising an end to the pandemic—it seemed as good a si2020/12/23
-
2021 forecast: Up for FDA review? Don't hold your breath if COVID-19 continues to delay site inspectionsBringing a therapy to market is a monumental undertaking by any drugmaker, a feat requiring years in the clinic and reams of cash. But when push comes to shove, a drug's commercial hopes must eventua2020/12/23
-
Horizon's Tepezza supply dwindles as manufacturer Catalent pivots to Warp Speed vaccinesHorizon's thyroid eye disease med Tepezza will run scarce from the end of December into 2021, the company said Thursday, blaming COVID-19 vaccine orders that are dominating the agenda at contract man2020/12/21